Hypotensive effect of atorvastatin in hypertensive patients: The association among flow-mediated dilation, oxidative stress and endothelial dysfunction

Archives of Medical Science

Volumn 7, Issue 6, 2011, Pages 955-962

  Tycinska, Agnieszka M ^a   Janica, Jacek ^a   Mroczko, Barbara ^a   Musial, Wlodzimierz J ^a   Sawicki, Robert ^a   Sobkowicz, Bozena ^a   Kaminski, Karol ^a   Lebkowska, Urszula ^a   Szmitkowski, Maciej ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Arterial hypertension; Endothelin 1; Flow mediated dilation; Nitric oxide; Peroxides; Total antioxidant status

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTIOXIDANT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN 1; NITRIC OXIDE; PEROXIDE;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; CROSSOVER PROCEDURE; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

EID: 84855382209     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: 10.5114/AOMS.2011.26606     Document Type: Article

References (30)

1. Vanhoutte PM. Endothelial dysfunction: the first step toward coronary arteriosclerosis. Circ J 2009; 73: 595-601.
2. Taddei S, Virdis A, Ghiadoni L, Sudano I, Notari M, Salvet ti A. Vasoconstriction to endogenous endothelin-1 is increased in the peripheral circulation of patients with essential hypertension. Circulation 1999; 100: 1680-3. (Pubitemid 29485248)
3. Romero-Alvira D, Roche E. High blood pressure, oxygen radicals and antioxidants: etiological relationships. Med Hypothesis 1996; 46: 414-20. (Pubitemid 26140141)
4. Banach M, Mikhailidis DP, Kjeldsen SE, Rysz J. Time for new indications for statins? Med Sci Monit 2009; 15: MS1-5.
5. Borghi C, Veronesi M, Prandin MG, Dormi A, Ambrosioni E. Statins and blood pressure regulation. Curr Hypertens Rep 2001; 3: 281-8.
6. Kuklinska A, Mroczko B, Musial WJ, et al. Influence of atorvastatin on blood pressure control in treated hypertensive, normolipemic patients - an open, pilot study. Blood Press 2010; 19: 260-6.
7. Corretti MC, Anderson TJ, Benjamin EJ, et al.; International Brachial Artery Reactivity Task Force. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 39: 257-65. (Pubitemid 34084631)
8. Kuklinska A, Mroczko B, Musial WJ, et al. High-sensitivity C-reactive protein and total antioxidant status in patients with essential arterial hypertension and dyslipidemia. Adv Med Sci 2009; 54: 225-32.
9. Kuklinska A, Mroczko B, Musial WJ, et al. Diagnostic biomarkers of essential arterial hypertension: the value of prostacyclin, nitric oxide, oxidized-LDL, and peroxide measurements. Int Heart J 2009; 50: 341-51.
10. Sitia S, Tomasoni L, Atzeni F, et al. From endothelial dysfunction to atherosclerosis. Autoimmun Rev 2010; 9: 830-4.
11. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111-5.
12. Ast J, Jablecka A, Bogdanski P, Smolarek I, Krauss H, Chmara E. Evaluation of the antihypertensive effect of L-arginine supplementation in patients with mild hypertension assessed with ambulatory blood pressure monitoring. Med Sci Monit 2010; 16: CR266-71.
13. Koh KK, Quon MJ, Waclawiw MA. Are statins effective for simultaneously treating dyslipidemias and hypertension? Atherosclerosis 2008; 196: 1-8.
14. Borghi C, Dormi A, Veronesi M, Sangiorgi Z, Gaddi A. Brisighella Heart Study Working Party Association between different lipid-lowering treatment strategies and blood pressure control in the Brisighella Heart Study. Am Heart J 2004; 148: 285-92. (Pubitemid 39092793)
15. Williams B, Lacy PS, Cruickshank JK, et al.; CAFE and ASCOT Investigators. Impact of statin therapy on central aortic pressures and hemodynamics: principal results of the Conduit Artery Function Evaluation-Lipid-Lowering Arm (CAFE-LLA) Study. Circulation 2009; 119: 53-61.
16. Mancia G, Parati G, Revera M, et al. Statins, antihypertensive treatment, and blood pressure control in clinic and over 24 hours: evidence from PHYLLIS randomised double blind trial. BMJ 2010 25; 340:c1197. doi: 10.1136/bmj.c1197.
17. Bellia A, Rizza S, Galli A, et al. Early vascular and metabolic effects of rosuvastatin compared with simvastatin in patients with type 2 diabetes. Atherosclerosis 2010; 210: 199-201.
18. Kashyap MK, Yadav V, Sherawat BS, et al. Different antioxidants status, total antioxidant power and free radicals in essential hypertension. Mol Cell Biochem 2005; 277: 89-99. (Pubitemid 41236190)
19. Kuryata OV, Yegorova YV. The influence of low-dose atorvastatin on lipid levels and endothelial vascular function in patients with significant coronary artery stenosis. Kardiol Pol 2006; 64: 44-8.
20. Koh KK, Quon MJ, Han SH, et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 2004; 110: 3687-92. (Pubitemid 39665258)
21. Foss OP, Graff-Iversen S, Istad H, So/yland E, Tjeldflaat L, Graving B. Treatment of hypertensive and hypercholesterolaemic patients in general practice. The effect of captopril, atenolol and pravastatin combined with life style intervention. Scand J Prim Health Care 1999; 17: 122-7. (Pubitemid 29339650)
22. O'Callaghan CJ, Krum H, Conway EL, et al. Short term effects of pravastatin on blood pressure in hypercholesterolaemic hypertensive patients. Blood Press 1994; 3: 404-6. (Pubitemid 24380427)
23. Borghi C, Prandin MG, Costa FV, et al. Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol 2000; 35: 549-55. (Pubitemid 30185454)
24. Ge CJ, Lu SZ, Chen YD, Wu XF, Hu SJ, Ji Y. Synergistic effect of amlodipine and atorvastatin on blood pressure, left ventricular remodeling, and C-reactive protein in hypertensive patients with primary hypercholesterolemia. Heart Vessels 2008; 23: 91-5. (Pubitemid 351494086)
25. Mancia G, Parati G. Guiding antihypertensive treatment decisions using ambulatory blood pressure monitoring. Curr Hypertens Rep 2006; 8: 330-7. (Pubitemid 44268837)
26. O'Brien E, Asmar R, Beilin L, et al.; European Society of Hypertension Working Group on Blood Pressure Monitoring. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens 2003; 21: 821-48. (Pubitemid 36677141)
27. Sethi A, Arora RR. Ambulatory blood pressure as a predictor of cardiovascular risk. Arch Med Sci 2009; 5: 3-9.
28. de Matthaeis A, Greco A, Serviddio G, Stramaglia G, Vendemiale G. Endothelial dysfunction evaluated by flow mediated dilation is strongly associated to metabolic syndrome in the elderly. Aging Clin Exp Res 2009; 22: 303-7.
29. Glorioso N, Troffa C, Filigheddu F, et al. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 1999; 34: 1281-6. (Pubitemid 30002395)
30. Kostapanos MS, Milionis HJ, Elisaf MS. Current role of statins in the treatment of essential hypertension. Expert Opin Pharmacother 2010; 11: 2635-50.